Skip to main content
main-content

05-06-2021 | ASCO 2021 | Conference coverage | Video

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC

Stephen Liu talks through the latest findings from the ARROW trial of pralsetinib for patients with RET fusion-positive advanced non-small-cell lung cancer (3:18).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits